August 1992, Volume 42, Issue 8

Review Articles


Imran Iqbal  ( Department of Paediatrics, Nishtar Medical College and Hospital, Multan. )

The syndrome of acute inflammatory idiopathic polyneuropathy is well known, the predominently motor type of which is recognised by the name of Guillain-Barre Syndrome (GBS)1, in which the maximum neurological deficit develops rapidly in days, plateaus for weeks and then subsides with the recovery occurring in weeks to months2. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has earned a compara­tively recent recognition over the last 30 years or so. Its characteristics and diagnostic criteria have been described3 and are undergoing refinement with time4,5. Its importance is underscored by the fact that it repre­sents about 21% of all initially undiagnosed neuropathies6. CIDP shares with acute inflammatory demyelinat­ing polyradiculoneuropathy, the features of dcniyclina­tion and mononuclear infiltration of peripheral nerves and its cytoalbuminologic dissociation in the cerebro­spinal fluid. It differs in temporal evolution, course and prognosis and in its response to treatment7. Although the earlier descriptions of cases of Gull­lain-Barre Syndrome (GBS) contain some patients who had a slower onset of disease and a protracted course8, Austin9 is crcdited with first highlighting the disorder and indicating its responsiveness to corticosteroids. He described two cases of recurrent polyncuropathy and received thirty others with a similar case history going back to 1894. For a longtime, there were many different terminologies used by different authors to describe this disorder including chronic Guillain-Barre Syndrome10, chronic relapsing neuropathy11, recurrent and chronic relapsing Guillain-Barre Polyneuritis12, relapsing motor polyneuropathy13. and steroid responsive recurrent polyneuropathy14. The term Chronic Inflammatory Polyradiculoneuropathy was first used by Dyck et al3 who described natural history and pathological features of the disease in a large series of patients. Later on, the word demyelinating was added by him15. Since then many other scientists have described their experience with the condition and a few large series have been published4,16. Recently a consensus report on research criteria for diagnosis of CIDP has come out5.


CIDP usually begins in a slowly progressive fashion in months but may, uncommonly, have a rapid initial onset of weakness indistinguishable from acute GBS16. History of preceding infection is obtained much less commonly as compared to GBS, averaging in about 20-30% of patients2. It affects all age groups3,17 and is commoner in males2,4. The illness generally tends to be less severe than typical cases of acute GBS and most prominent symptom. are of symmetric muscular weakness2 which is proxim. ‘1 as well as distal4. Reflexes are usually lost within a few months of onset of disease2. Weakness of musculature supplied by cranial nerves, most commonly facial or oropharyngeal weakness is seen in about 10-15% of cases3,4,16. Sensory symptoms are present in most of the patients4,7. A pure motor neuropathy or one with only sensory symptoms have been described but arc uncom­mon7,16 . Rarely clinical features include ataxia, tremor and papilledema16. Distinguishing feature of CIDP is a course prolonged over the years with fluctuations in the severity of symptoms2,7,16.


Cerebrospinal fluid
Albuminocytologic dissociation in cerebrospinal fluid (CSF) is typically seen. CSF albumin levels reported in two of the large series of patients averaged at 137.6±112.6 mg per decilitre3 and 134±112 mg per decilitre4. Uncommonly (0-20% of patients) it can be normal2. Pleoxytosis of CSF is quite rare and was seen in only 0-10% of patients2.
Nerve conduction studies
Slowing of motor nerve conduction velocities to less than 60%4 and prolonged distal latencies in several nerves are present weeks to months after the onset of disease2. Amplitude of muscle action potential is reduced and afferent nerves are similarly affected7. Multifocal conduction blocks have also been emphasised as a prominent feature2.
Peripheral nerves as well as spinal nerve roots are affected by the pathological process. Segmental demyclination, remyclination, onion-bulb formation and mononuclear cell infiltration (neural and perivascular) have been found by various investigators7. In a small proportion of cases axonopathy has been detected. A few patients show absence of any pathological changes4. Mechanism of these changes is not very clear. Some of the researchers have found immunoglobulin deposits on the nerves of CIDP patients18.
Differential diagnosis
Relapses of acute GBS may look like CIDP but are distinguishable On the basis of their clinical course which does not get prolonged more than weeks with partial or complete recovery in between. CIDP, on the other hand, has a slower evolution and a protracted course going in months and years2,16. Other types of neuropathies that may sometimes present a clinical picture similar to that of CIDP need to be excluded. Common among these would be hereditary neuropathy, some of the neuropathies associated with systemic diseases and others associated with neoplastic and paraneoplastic disorders. Any family history of neuropathy or presence of bony abnormalities in the patient would need nerve conduction studies of immedi­ate relatives. Dejerine-Sottas neuropathy (HMSN-III) may be specifically confusing as it can lead to thicker nerves as in CIDP. Some cases of hereditary neuropathy have been found responsive to prednisolone, a feature which remains unexplained7,19. Associations have been reported between an illness resembling CIDP and human immuno-deficiency virus infections, non-systemic vas­culitis, systemic lupus erythematosis, sarcoidosis, ulcera­tive colitis and regional enteritis2,7. Polyradiculopathies also occur in association with lymphomas, myelomas and monoclonal gammopathies. Detailed evaluation and necessary investigations to exclude these disorders are part of the diagnostic process7.


Cortico Steroids
Steroid responsiveness of CIDP was first described by Austin in 1958. Since then most of the researchers have confirmed his observation although the response to steroids is variable and often partial. Dyck et at3 found that, in their patients, steroids resulted in improvement in 39%, worsening in 14% and had no effect in 47%. Oh20 reported improvement in all the 10 cases but 5 of these relapsed when steroids were withdrawn. Dyck et al15 also showed, through a controlled trial, that steroid therapy resulted in a small but significant improvement. Mc­Combe et al16 reported improvement in 65% of their patients treated with steroids. Some researchers have tried antimitotic drugs like azathioprine in combination with steroids in patients poorly responding to steroids or relapsing after steroid treatment. They “appear to benefit” 16 in some cases while in others no benefit was seen21.
Server and co-workers22 reported plasma exchange to be beneficial in treatment of CEDP. Dyck et al. 23 confirmed its utility in a controlled trial. McCombe et al. 16 found it useful in 61% patients.
Gammaglobu fins
Infusions of intravenous gammaglobulin (IVIG) have also been used. In one large series, 17% reached complete remission, 40% improved but needed intermittent inlusions to maintain improvement, 4% nan a snort lasting improvement and 38% did not show any response24. Cornblath25 mentions that pooling of data shows that clinically significant responses have been observed in 68% of patients treated with this modality. There seems to be no concensus on the treatment regime for CIDP. Many of the authorities utilise all the three modalities of treatment in accordance with patient response. Dyck and Arnason7 mention prednisolone as the drug of choice, but McCombe et al. 16 think that plasma exchange can be used in preference to cor­ticosteroids. Barohn et al. 4 used steroids initially but also utilised plasmapheresis in addition for severely affected or poorly responding patients. Von Doom et al24 mention that WIG results in a much rapid improvement (days to weeks) as compared to months for steroid therapy. Ropper et al2 recommend WIG before beginning steroids in worsening patients and advise follow-up with plasma exchanges in unsuccessful cases.
Course and prognosis
The characteristic of CIDP is a chronic progressive or relapsing course spread over the years2,16. About 67% of the patients have a relapsing course15,16 which can be further described into relapses during a monophasic course, a remitting and relapsing course and relapses during a progressive course2. The progressive course without relapses will be seen in about 15% of patients, progressions being manifested in a continuous or a step wise fashion2,7. The rest of the patients follow a slow monophasic course characterised by worsening of the condition followed by improvement. Course of the disease is usually modified by treatment although subsequent relapses are frequent4. Patients with a relapsing course tend to have a more favourable prognosis as compared to those with a chronic progressive course16. In a large series of patients 73% were recovered or only mildly disabled after an average 10 years of follow up16 while in another series only 40% of patients were in complete or partial remission without medication after a 34 month average follow-up4.


I am thankful to Dr. Lloyd Shield, Director of Neurology, The Royal Children’s Hospital, Melbourne, Australia for providing the relevant literature and to Ms. Marie Patrick for typing the manuscript.


1. Guillain, 0., Bare. J.A. and Strohl. A. Sur un syndrome de radiculoneurite avec hyperalbuminosedu liquide cephaloeachidien sans reaction celluloise: remarquessurles caracteres cliniques et graphiques des reflexes tendineux. Bull Soc. Med. Hosp. Paris, 1916:40:1462.
2. Ropper. All.. Wijdicks, BALM., Trace, B.T. Guillain-Barre syndrome. Contemporary Neurology Series. PA. DavisCompany. Philadelphia, 1991; pp. 128-45.
3. Dyck, PA., Lais, AC., Ohta. M., Bastron, J.A. Okazaki, H. and Groover, R.V. chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc.. 1975:50:621-37.
4. Barohn, R.J., Kiasel, J.T., Warmolta, J.R. and MendeR JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol., 1989; 46:878-84.
5. Taskforce (American Academy of Neurology) Reaearch criteria for diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology. 1991;41:617-8.
6. Dyck, P.J., Oviatt, K.F. and Lambert. E.H. Intensive evaluation of referred unclassified neuropathiesyields improved diagnosis. Ann. Neurol., 1981; 10:222-26.
7. Dyck, PS and Arnaaon, B.J.W. Chronic inflammatory demyclinating polyradiculoneuropathy, in peripheral neuropathy. Edited by Dyck. Thomas, Lambert, Bunge Philadelphia, Saunders, 1984; pp. 2101-4.
8. DeJong. RN. The Guillain-Barre syndrome. Polyradiculoneuritis with albumino­cytologic dissociation. Arch. Neurol. Psych., 1940; 44:1044.
9. Austin. J.H. Recurrent polyneuropathies and their corticoateroid treatment Brain, 1958; 81:157-92.
10. Hinman, R.C. and Magee, ICR. Guillain-Barre syndrome with slow progressive onset and peraistentelevation of spinal fluid protein. Ann. Intern. Med., 1967; 67:1007-12.
11. Dyck, P.J., Gultrecht, J.A., Bastron, J.A., Karnea, WE. and Dale, J.D. Hiatologic and teaaed fibre measurements of aural nerve in disorders of lower motor and primary sensory neurons. Mayo Clin. Proc., 1968;43:81- 123.
12. Thomaa, P.K.. Lascelles, R.G., Hallpike, J.F. and Hewer, ltL Recurrent and chronic relapsingGuillain-Barre polyneuritia. Brain, 1969; 92:589-606.
13. Aahworth, B. and Smyth, G.E. Relapsing motor polyneuropathy. Acta Neurol. Scand., 1969; 45:342-50.
14. Devivo, D.C and Engel. W.K. Remarkable recovery of a steroid- responsive recurrent polyneuropathy. J.Neurol. Neurosurg. Psychiatry, 1970; 33:62-69.
15. Dyck, Pi., O\\\'Brien, P.C., Ovistt, K.F., Dinapoli, R.P., Daube, J.R., Bartleson, 1.0., Mokri, B.. Swift, T., Low, P-A and Windebank, A.J. Predniaone improves chronic inflammatory dcmyelinating polyradiculoneuropathy more than no treatment Ann. Neurol., 1982; 11:136-41.
16. McCombe. PA.. Pollard, 1.0. and McLeod, 1.0. Chronic inflammatory demyelinating polyradiculoneuropathy. Brsin, 1987: 110:1617-30.
17. Colan, R.V., Snead, O.C., Oh. 5.1. and Benton, J.W. Steroid- responsivepolyneuropathy with subacute onset in childhood. J. Paedistr., 198% 97:374-77.
18. Dalakas. MC. and Engel, W.K. Immunoglobulin and complement deposits in nervcs of patients with chronic relapsing Polyneuropathy. Arch. Ncurol., 1980;37:367-40
19. Dyck, P.J., Swanson, C.J., Low, P.A., Bartleson, J.D. and Lambert, E.H. Prcdnisone­responsive heredatory motor and sensory neuropathy. Mayo Clin. Proc., 1982:57:239-46.
20. Oh. Si. Subacute demyelinating polyneuropathy responding to corticosteroid treat­ment Arch. Neurol., 1978; 35:509.
21. Dyck, P2., Q’Brien, P.C., Swanson, C, Low, P., and Daube, J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy: Neurol Cleveland, 1985; 35:1173- 76.
22. Server, AC, Leikowith, J., Braine, H. and McKhann, G.M. Treatmcnt of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann. Neurol., 1979; 6:258-61.
23. Dyck, P.1., Daube, J., O’Brien, P., Pineda, A., Low, PA.. Windebank, Al. and Swanson, C-Plasma exchange in chronic inflammarorydemyelinating polyradiculoncuropsthy. N. EngI. J. Med., 1986; 314:461-6S. ­
24. van Doom, P.A., Vermenlen, 84., Brand, A, Mulder, P.G.H. and Busch, H.P.M. Intravenous immunoglohutn treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol., 1991; 48:217-20.
25. Cornblath, D.R., Chaudry, V. and Griffin. J.W. Treatment of chronic inflammatory’ demyelinating potyneuropathy with intravcnous immunoglobulin. Ann. Neurol., 1991; 30:104-6.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: